演題抄録

International Symposium

開催概要
開催回
第51回・2013年・京都
 

Current issues and challenges to control HCC in Asia

演題番号 : IS1-3

[筆頭演者]
Kwang-Hyub Han:1 

1:Department of Internal Medicine, Yonsei University College of Medicine, Korea

 

Chronic hepatitis B and C estimated to affect over 500 million people worldwide. Approximately 340 million people living with chronic hepatitis B or C in Asia, which is 65% of the total number worldwide. In addition, at least two thirds of the people who die each year from HCC live in the Asia-Pacific regionAt present, inadequate public resources are being allocated to prevention, control and surveillance programs for HCC in developing Asian countries. The majority of HCC patients in Asia except Japan are diagnosed at the advanced stages of presentation due to the lack of public awareness and nationwide surveillance program and limited resources of diagnostic modality. Therefore, potentially curative treatment for HCC is not feasible.Key Barriers for Surveillance, Diagnosis and Treatment in Asia are lack of awareness for screening and surveillance among at-risk populations, health-care providers and policy-makers. Limited resources of diagnostic imaging modality in many Asian countries make an accurate early diagnosis of HCC difficult. For the management of HCC, the facility for team approach of HCC management will be needed in Asian countries. For HBV related HCC prevention, the estimated global coverage rate of infant HBV vaccination has been remarkably increased from less than 1% in 1990 to 75% in 2010. Therefore disease burden of HBV and HBV related HCC incidence will be proportionally decreasing in Asia. However, burden of HCV will be increasing and the prevalence may remain high in Asia. Therefore non-B (HCV or NBNC) related HCC incidence will be proportionally increasing. New strategy to screen and control of non-B related chronic liver diseases will be necessary to control HCC in Asia.

前へ戻る